Project Grant K99AR081926
Award Date 9/15/25
Completion Date 8/31/27
Dollars Obligated $124K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98109, USA
Similar Awards
- This federal Project Grant award of $175,500 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), aims to investigate the role of alternative splicing in Facioscapulohumeral Muscular Dystrophy (FSHD). The research project, performed by The Washington University, has three key objectives: 1) Characterize the interactions between the transcription factor DUX4 and RNA in...
- This federal Project Grant award of $671,240 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) supports research to develop enhanced dystrophin gene therapies for Duchenne muscular dystrophy (DMD). The University of Washington will conduct this research from January 2025 through December 2029. The project aims to design and test micro-, mini-, and full-length dystrophin gene...
- This Project Grant award from the National Center for Advancing Translational Sciences (NCATS), CFDA 93.350, provides $313,372.00 to D4Z4 Medicine, Inc. to develop a long-read sequencing-based molecular diagnostic assay for Facioscapulohumeral Muscular Dystrophy (FSHD). The project aims to standardize and validate the long-read sequencing assay, increase its capacity by adding target regions, and optimize a bioinformatics pipeline with a user-friendly interface for analyzing the sequencing data....
- The National Institutes of Health's National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded New York University School of Medicine $409,311.92 under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) from April 5, 2021 to January 25, 2022. The project grant funding supports research into the role of T follicular helper (TFH) cells in the pathogenesis of dermatomyositis, a severe inflammatory myopathy. Specifically, the award will fund studies to...
- This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research federal grant program (CFDA 93.846), provides $1,622,775.00 to the Van Andel Research Institute (VAI) in Grand Rapids, Michigan to study the critical role of mitochondrial oxidative metabolism in regulating muscle satellite cell fate and function. The research aims to definitively determine the metabolic requirements...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $439,791 Project Grant to The University of Texas Southwestern Medical Center on March 1, 2025 under the Arthritis, Musculoskeletal and Skin Diseases Research federal grant program (CFDA 93.846). The grant supports research to investigate the molecular mechanisms of myoblast fusion, which is essential for skeletal muscle development and regeneration. The research aims to understand the cellular and...
- This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), is funding research on the role of HOX-expressing interstitial cells in muscle growth, homeostasis, and regeneration. The $557,357 award, effective from March 14, 2025 through February 28, 2030, will support a University of Wisconsin-Madison research project investigating the ability of a...
- This $190,137 Cooperative Agreement was awarded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The agreement aims to bridge the gap between genetic testing and patient care for muscular dystrophies and myopathies by defining the clinical relevance of genes and genetic sequence variants associated with these disorders. Key efforts include evaluating the clinical validity of...
- This federal Project Grant award of $471,513 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) supports research to investigate the mechanisms underlying neuromuscular diseases where glycosylation is disrupted. The University of Maine System, through its Research & Sponsored Program division, will use a zebrafish model to study how loss of the dolichylphosphate mannose...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $676,841 Project Grant titled "LEVERAGING HUMAN MUSCULOSKELETAL DEVELOPMENT TO IDENTIFY CAUSAL DISEASE VARIANTS" to President and Fellows of Harvard College. The award period runs from August 1, 2025 to July 31, 2030 under the Arthritis, Musculoskeletal and Skin Diseases Research federal grant program (CFDA 93.846). The objective of the project is to conduct targeted functional genomic studies...